Results 61 to 70 of about 218,137 (296)

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, Volume 20, Issue 6, Page 1398-1419, June 2026.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

PD-L1 and PD-1 in immune regulation and their implications in blood cancers

Advances in Cancer Biology - Metastasis
Because of emerging opportunities for cancer immunotherapy, the capacity to suppress the immune system in order to cure and eradicate cancer is currently a topic of intense study.
Parisa Shiri Aghbash, Faezeh Mehdizadeh, Ghazal Pourbeiragh, Yalda Yazdani, Hossein Bannazadeh Baghi, Abolfazl Jafari Sales, Mehrdad Pashazadeh, Parisa Kangari   +7 more
doaj   +1 more source

Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells

Frontiers in Immunology, 2017
The programmed death-1 (PD-1) and its ligand PD-L1 (B7-H1) signaling pathway has been the focus of much enthusiasm in the fields of tumor immunology and oncology with recent FDA approval of the anti-PD-1 antibodies pembrolizumab and nivolumab and the ...
Rachel M. Gibbons Johnson, Haidong Dong, Haidong Dong   +2 more
doaj   +1 more source

D-1 / PD-L1 EXPRESSION IN INVASIVE BREAST CARCINOMA / CANCER

Pakistan Armed Forces Medical Journal, 2021
Objective: To investigate the immunohistochemical expression of PD-1 and PD-L1 in breast cancer cases and its correlation with clinicopathological factors. Study Design: Cross sectional study. Place and Duration of Study: Histopathology department,
Sammeen Salim, Muhammad Asif, Rabia Ahmed, Muhammad Tahir Khadim   +3 more
doaj   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, Volume 20, Issue 6, Page 1453-1472, June 2026.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

PD‐1/L1 inhibitors can improve but not replace chemotherapy for advanced urothelial carcinoma: A systematic review and network meta‐analysis

Cancer Innovation, 2023
Background Programmed cell death‐1/ligand 1 inhibitors are a new treatment strategy for advanced urothelial carcinoma. Therefore, a comparative evaluation of their efficacy and toxicity compared with chemotherapy is necessary.
Longkun Mao, Meihua Yang, Xinxiang Fan, Wenjie Li, Xiaodong Huang, Wang He, Tianxin Lin, Jian Huang   +7 more
doaj   +1 more source

A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC

JTO Clinical and Research Reports, 2022
Introduction: The real-world effectiveness of combination treatment with cytotoxic chemotherapy and programmed cell death protein-1 or programmed death-ligand 1 inhibitor for NSCLC, especially for the elderly (aged ≥75 y) or those with poor performance ...
Daichi Fujimoto, MD, Satoru Miura, MD, PhD, Kenichi Yoshimura, MD, PhD, Kazushige Wakuda, MD, Yuko Oya, MD, Koji Haratani, MD, PhD, Shoichi Itoh, MD, Takehiro Uemura, MD, PhD, Ryotaro Morinaga, MD, PhD, Takayuki Takahama, MD, PhD, Kazuhisa Nakashima, MD, Motoko Tachihara, MD, PhD, Go Saito, MD, Junko Tanizaki, MD, PhD, Kohei Otsubo, MD, PhD, Satoshi Ikeda, MD, Hirotaka Matsumoto, MD, Satoshi Hara, MD, Akito Hata, MD, Takeshi Masuda, MD, PhD, Nobuyuki Yamamoto, MD, PhD   +20 more
doaj   +1 more source

CTLA-4 and PD-1 ligand gene expression in epithelial thyroid cancers [PDF]

, 2018
The dysregulation of PD-1 ligands (PD-L1 and PD-L2) and CTLA-4 ligands (CD80 and CD86) represents a tumor strategy to escape the immune surveillance. Here, the expression of PD-L1, PD-L2, CD80 and CD86 was evaluated at mRNA level in 94 patients affected ...
Antonelli, Alessandro, Arcieri, Stefano, Baldini, Enke, Barollo, Susi, Carbotta, Giovanni, Catania, Antonio, Fallahi, Poupak, Mian, Caterina, Monti, Massimo, Palmieri, Andrea, Pironi, Daniele, Sorrenti, Salvatore, Tartaglia, Francesco, Tuccilli, Chiara, Ulisse, Salvatore, Vergine, Massimo   +15 more
core   +3 more sources

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Percentages of PD-1+CD4+T cells and PD-L1+DCs are increased and sPD-1 level is elevated in patients with immune thrombocytopenia

Human Vaccines & Immunotherapeutics, 2018
The present study is to measure the expression of programmed death (PD)-1 / programmed death ligand-1 (PD-L1) negative costimulatory molecules, soluble format sPD-1 in patients with immune thrombocytopenia (ITP), and to investigate their correlation with
Yingying Wang, Nannan Pang, Xinyou Wang, Ying Liu, Xiujuan Wang, Lei Wang, Mingling Sun, Halida Yasen, Fang Zhao, Wenxia Fan, Xinhong Guo, Jianbing Ding   +11 more
doaj   +1 more source